GLP Watchdog

GoodRx vs Push Health

Neither GoodRx nor Push Health has an FDA warning letter on record. Push Health publishes no GLP-1 price we could capture. GoodRx starts at $149 a month for Foundayo (orforglipron) pill.

To see where both sit among the other sellers, read our best weight-loss injection providers board.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The record

GoodRx / Push Health

GoodRx logo

GoodRx

7.8/10

Push Health logo

Push Health

4.1/10

FDA warning letters
None on record
None on record
Pharmacy
Brand-name only; no compounding
None named in our record
Lowest standing price
$149/moFoundayo (orforglipron) pill
No GLP-1 price published
States
48 states
No state list published
Checked
Prices captured Record checked October 2026
Prices captured Record checked September 2026
Visit GoodRx
Visit Push Health

Neither GoodRx nor Push Health pays us. Links to them earn nothing. Scores: GoodRx 7.8, Push Health 4.1. How we are paid

What the record shows

  1. 01

    Neither GoodRx nor Push Health has an FDA warning letter on record.

  2. 02

    Push Health names no compounding pharmacy in our record. GoodRx sells brand-name medication only.

  3. 03

    Push Health publishes no GLP-1 price we could capture. GoodRx starts at $149 a month for Foundayo (orforglipron) pill.

  4. 04

    Only GoodRx lists a price for brand-name tirzepatide pen and Foundayo (orforglipron) pill.

  5. 05

    GoodRx lists 48 states. Push Health publishes no state list.

Prices and terms, product by product

A price is set against the other side only for the same product, and only when both are standing monthly or 4-week rates. Those pairs are compared by yearly cost.

GoodRx

Push Health

Brand-name tirzepatide pen

$299/mo

$3,588 a year

Not sold or not priced
Foundayo (orforglipron) pill

$149/mo

$1,788 a year

Not sold or not priced
Cancel any time
Yes, stated
Yes, stated
Minimum term
None
None
Refunds
Services and medication are generally non-refundable
Full refund if you cancel before the provider writes a prescription; none after

Read off each seller’s own pages. GoodRx: October 30, 2026. Push Health: September 28, 2026. Every plan and dose we hold is on the full review.

The case for each

The case for GoodRx

7.8/10
  • Sells brand-name tirzepatide pen and Foundayo (orforglipron) pill, which Push Health does not price
Visit GoodRx

The case for Push Health

4.1/10

The record gives Push Health no edge on this pair.

  • Names no compounding pharmacy
  • Publishes no state list
  • Publishes no GLP-1 price
Visit Push Health

Scores

GoodRx 7.8 · Push Health 4.1 out of 10. Six weighted parts.

Value25%

8.7A
vs
B
3.0

Effectiveness25%

10.0A
vs
B
5.0

User Experience15%

5.0A
vs
B
3.0

Trust & Safety15%

6.0A
vs
B
4.0

Accessibility10%

9.7A
vs
B
5.0

Support10%

5.0A
vs
B
5.0

The score is the same formula for every seller. Payment does not enter it. Method

GoodRx vs Push Health: questions

Neither GoodRx nor Push Health has an FDA warning letter on record. Letters are matched to a seller by company, domain and address, never by a similar name.
Push Health names no compounding pharmacy in our record. GoodRx sells brand-name medication only.
GoodRx states you can cancel at any time; refunds: services and medication are generally non-refundable. Push Health states you can cancel at any time; refunds: full refund if you cancel before the provider writes a prescription; none after.
Neither GoodRx nor Push Health pays us. Links to them earn nothing. Scores: GoodRx 7.8, Push Health 4.1.

Other sellers we are paid by

Affiliate partners outside this pair. Each has its own record and review, scored the same way.

Sellers closest to these two

Matched on molecule, form and price. Every pair we list · The register

Brand names on this page are registered marks. Novo Nordisk holds Wegovy®, Ozempic® and Rybelsus®; Eli Lilly holds Zepbound®, Mounjaro® and Foundayo®. Neither company has any tie to GLP Watchdog. Trademarks